Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorIlanbey, Bilal
dc.contributor.authorElmas, Ömer Faruk
dc.contributor.authorSözmen, Eser Yıldırım
dc.contributor.authorGünay, Ümran
dc.contributor.authorDemirbaş, Abdullah
dc.contributor.authorAtasoy, Mustafa
dc.contributor.authorTürsen, Ümit
dc.contributor.authorLotti, Torello
dc.date.accessioned2023-05-30T08:49:08Z
dc.date.available2023-05-30T08:49:08Z
dc.date.issued2021en_US
dc.identifier.citationIlanbey, B., Elmas, Ö. F., Sözmen, E. Y., Günay, Ü., Demirbaş, A., Atasoy, M., ... & Lotti, T. (2021). A novel marker of systemic inflammation in psoriasis and related comorbidities: Chitotriosidase. Turkish Journal of Medical Sciences, 51(5), 2318-2323.en_US
dc.identifier.issn13000144
dc.identifier.urihttps://doi.org/10.3906/SAG-2101-137
dc.identifier.urihttps://hdl.handle.net/20.500.12513/5107
dc.description.abstractBackground/aim: Chitotriosidase (ChT) is an enzyme secreted by activated macrophages and neutrophils in response to proinflammatory signals. There is growing evidence indicating that ChT activity reflects the systemic inflammatory status. This study aimed to investigate whether serum ChT activity increased in patients with psoriasis and related comorbidities. Materials and methods: This cross-sectional study included 53 (28 with associated comorbidities and 25 without comorbidities) patients with psoriasis and 52 healthy volunteers. All participants underwent laboratory investigations for serum ChT levels, complete blood count, erythrocyte sedimentation rate, C-reactive protein, and serum lipid levels. Results: The patients with psoriasis showed significantly higher levels of ChT activity as compared to the healthy controls (23.5 ± 11.4 vs. 17.5 ± 10.4 μmol/mL/hour; p = 0.015). Additionally, the ChT activity was significantly higher in patients with comorbidities than in those without (p = 0.042). Conclusion: Our data support the pathogenetic role of inflammatory processes induced by macrophage activation in patients with psoriasis and related comorbidities. We believe that high ChT activity in patients with psoriasis may serve as an early prediction of the possible related comorbidities. © TÜBİTAK.en_US
dc.language.isoengen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.isversionof10.3906/SAG-2101-137en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChitotriosidaseen_US
dc.subjectComorbidityen_US
dc.subjectMacrophageen_US
dc.subjectPsoriasisen_US
dc.titleA novel marker of systemic inflammation in psoriasis and related comorbidities: Chitotriosidaseen_US
dc.typearticleen_US
dc.relation.journalTurkish Journal of Medical Sciencesen_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorIDBilal İlanbey / 0000-0002-7614-281Xen_US
dc.identifier.volume51en_US
dc.identifier.issue5en_US
dc.identifier.startpage2318en_US
dc.identifier.endpage2323en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster